Physician profile
Elzbieta Stob
NPI 1902255185
$3,002.43
in general payments reported to CMS, 2019-2025
25 companies · $1,342 in 2025
The $1,342 reported for 2025 was more than what 84% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $228 · 2022: $223 · 2023: $494 · 2024: $716 · 2025: $1,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,492 · Education: $59.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,491.91 |
| Education | $59.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $370.38 | 2021-2025 | Tavneos, Krystexxa, Aranesp |
| Otsuka America Pharmaceutical, INC. | $337.23 | 2022-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $292.67 | 2021-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $261.80 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $217.83 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $194.59 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $154.86 | 2021-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $154.14 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $154.11 | 2023-2025 | Acthar |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $119.89 | 2023-2025 | |
| Akebia Therapeutics INC | $119.22 | 2021-2025 | Vafseo |
| Aurinia Pharma U.S., INC. | $107.59 | 2022-2024 | Lupkynis |
| Lilly USA, LLC | $65.78 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $63.79 | 2025 | Shingrix, Arexvy |
| Apellis Pharmaceuticals, INC. | $59.85 | 2025 | Empaveli |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $59.76 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.79 | 2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $48.63 | 2023 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $29.76 | 2025 | Ultomiris |
| Kyowa Kirin, INC. | $29.22 | 2025 | |
| Ani Pharmaceuticals, INC. | $24.98 | 2023 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $23.89 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $21.44 | 2024 | Crysvita |
| Amag Pharmaceuticals, INC. | $16.19 | 2021 | |
| Nuwellis, INC. | $16.04 | 2024 | Aquadex Smartflow Console |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elzbieta Stob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.